文献速递慢性肾脏病肾小球疾病

遗传或药理激活Nrf2加重慢性肾脏病小鼠蛋白尿

Genetic or pharmacologic Nrf2 activation increases proteinuria in chronic kidney disease in mice.
PubMed 文献 · Kidney Int · 2020-08-18

本研究利用Keap1FA/FA小鼠(Nrf2信号增强)和Nrf2敲除小鼠,在阿霉素、血管紧张素II或蛋白过载诱导的肾病模型中观察蛋白尿变化。结果显示Keap1FA/FA小鼠基线无蛋白尿但损伤后蛋白尿增加,伴肾小球硬化、足细胞损伤和间质纤维化;Nrf2敲除小鼠则被保护。药理Nrf2诱导剂CDDO-Im与血管紧张素II联用也显著增加蛋白尿,且不伴血压进一步升高。

要点

  • 遗传或药理激活Nrf2可加重慢性肾脏病小鼠的蛋白尿。
  • Nrf2敲除小鼠对蛋白尿有保护作用。
  • Nrf2诱导剂加重蛋白尿不依赖血压进一步升高。

核心结论

  • 小鼠中Nrf2诱导可能加重慢性肾脏病蛋白尿。

研究设计与样本

  • 使用Keap1FA/FA小鼠(Nrf2信号增强)和Nrf2敲除小鼠,在阿霉素、血管紧张素II或蛋白过载诱导的肾病模型中观察。
  • 另检测药理Nrf2诱导剂CDDO-Im与血管紧张素II联用的效果。

主要发现

  • Keap1FA/FA小鼠基线无蛋白尿,但损伤后蛋白尿增加,伴肾小球硬化、nephrin破坏和脱落、足细胞损伤、足突融合及间质纤维化。
  • Keap1FA/FA小鼠日间血压更高、心率更低(遥测法)。
  • Nrf2敲除小鼠免受蛋白尿。
  • 血管紧张素II联合CDDO-Im较单用血管紧张素II显著增加蛋白尿,此现象在Nrf2敲除小鼠中未观察到,且不伴血压进一步升高。
  • Nrf2在局灶节段性肾小球硬化、糖尿病肾病、纤维性肾小球肾炎和膜性肾病患者肾小球中上调。

临床怎么用

  • 临床使用药理Nrf2诱导剂(如巴多索隆甲基)治疗慢性肾脏病时需关注蛋白尿变化。

局限性

  • 研究为小鼠实验,人体结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The nuclear factor erythroid 2-related factor 2 (Nrf2) pathway upregulates key cellular defenses. Clinical trials are utilizing pharmacologic Nrf2 inducers such as bardoxolone methyl to treat chronic kidney disease, but Nrf2 activation has been linked to a paradoxical increase in proteinuria. To understand this effect, we examined genetically engineered mice with elevated Nrf2 signaling due to reduced expression of the Nrf2 inhibitor, Kelch-like ECH-associated protein 1 (Keap1). These Keap1FA/FA mice lacked baseline proteinuria but exhibited increased proteinuria in experimental models evoked by adriamycin, angiotensin II, or protein overload. After injury, Keap1FA/FA mice had increased glomerulosclerosis, nephrin disruption and shedding, podocyte injury, foot process effacement, and interstitial fibrosis. Keap1FA/FA mice also had higher daytime blood pressures and lower heart rates measured by radiotelemetry. Conversely, Nrf2 knockout mice were protected from proteinuria. We also examined the pharmacologic Nrf2 inducer CDDO-Im. Compared to angiotensin II alone, the combination of angiotensin II and CDDO-Im significantly increased proteinuria, a phenomenon not observed in Nrf2 knockout mice. This effect was not accompanied by additional increases in blood pressure. Finally, Nrf2 was found to be upregulated in the glomeruli of patients with focal segmental glomerulosclerosis, diabetic nephropathy, fibrillary glomerulonephritis, and membranous nephropathy. Thus, our studies demonstrate that Nrf2 induction in mice may exacerbate proteinuria in chronic kidney disease.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Rush BM, Bondi CD, Stocker SD, et al. Genetic or pharmacologic Nrf2 activation increases proteinuria in chronic kidney disease in mice. Kidney Int. 2020. PMID: 32818518. doi:10.1016/j.kint.2020.07.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。